Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan

Inaba et al., Research Square, doi:10.21203/rs.3.rs-2451986/v1
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 58% Improvement Relative Risk Death/hospitalization -127% Hospitalization -127% Molnupiravir  Inaba et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 294 patients in Japan Higher death/hosp. (p=0.22) and hospitalization (p=0.22), not sig. c19early.org Inaba et al., Research Square, January 2023 Favorsmolnupiravir Favorscontrol 0 0.5 1 1.5 2+
Retrospective 294 consecutive patients in Japan, showing higher risk of hospitalization/death with molnupiravir, without statistical significance.
Potential risks include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-14.
risk of death, 58.3% lower, RR 0.42, p = 1.00, treatment 0 of 84 (0.0%), control 1 of 210 (0.5%), NNT 210, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of death/hospitalization, 127.0% higher, RR 2.27, p = 0.22, treatment 5 of 84 (6.0%), control 8 of 210 (3.8%), odds ratio converted to relative risk, day 28.
risk of hospitalization, 127.0% higher, RR 2.27, p = 0.22, treatment 5 of 84 (6.0%), control 8 of 210 (3.8%), odds ratio converted to relative risk, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Inaba et al., 15 Jan 2023, retrospective, Japan, preprint, 9 authors.
This PaperMolnupiravirAll
Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan
Satoshi Inaba, Naoya Nishioka, Hisatoshi Okumura, Koshi Nakao, Yu Hattori, Shun Futamura, Tomohito Hattori, Kengo Okabe, Daichi Nishiyama
doi:10.21203/rs.3.rs-2451986/v1
Molnupiravir is among the antiviral agents used to treat COVID-19; however, reported data on the e cacy of this drug are based on results from unvaccinated patients. As such, the e cacy of molnupiravir among vaccinated patients during the B1.1.529 (Omicron) variant outbreak remains unknown. To address this issue, this study retrospectively analyzed data from 294 vaccinated patients with COVID-19 who had at least one risk factor, between May and October 2022. Patients were divided into the molnupiravir group and the control group to investigate the correlations of molnupiravir and other factors with rates of hospitalization and death (hospitalization/death) within 28 days of admission. Potential risk factors were also examined. The study ndings indicated that molnupiravir was not associated with the rate of hospitalization/death, while age ≥ 80 years, residence in a long-term care facility, and presence of chronic obstructive pulmonary disease were signi cantly associated with the rate of hospitalization/death. Although the current results suggest that the effect of vaccination in preventing severe illness against the Omicron variant is well maintained, additional studies on risk factors and outcomes are required to validate this study's ndings.
Author Contributions: NN and ND made substantial contributions to the conception of the work. HO, KN, YH, TH, and KO made signi cant contributions to the data analysis and interpretation. SI drafted the original manuscript. NN and other authors substantially contributed to the revision of the manuscript drafts. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Local Ethical Committee of Fukuchiyama City Hospital (Code number 4-26 and date of approval: September 28, 2022). Informed Consent Statement: Patient consent was waived due to the retrospective design and the ethical guidelines. Competing Interests: The authors declare no competing interests.
References
Abdelnabi, Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model, J. Infect. Dis
Agostini, Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance, J. Virol
Andrews, Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N. Engl. J. Med
Beigel, Remdesivir for the treatment of Covid-19 -Final report, N. Engl. J. Med
Bernal, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N. Engl. J. Med
Butler, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platformadaptive randomised controlled trial, Lancet
Cox, Wolf, Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat. Microbiol
De, Vito, Safety and e cacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience, J. Med. Virol
Fan, SARS-CoV-2 Omicron variant: Recent progress and future perspectives, Signal Transduct. Target. Ther
Gerayeli, COPD and the risk of poor outcomes in COVID-19: A systematic review and metaanalysis, EClinicalmedicine
Hammond, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N. Engl. J. Med
He, Hong, Pan, Lu, Wei, SARS-CoV-2 Omicron variant: Characteristics and prevention, Med
Iacobucci, Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show, BMJ
Johansen, Increased SARS-CoV-2 infection, protease, and in ammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells de ned with single-cell RNA sequencing, Am. J. Respir. Crit. Care Med
Kamal, Ramadan, Farraj, Bahig, Ezzat, The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review, Saudi Pharm. J
Kanda, Investigation of the freely available easy-to-use software 'EZR' for medical statistics, Bone Marrow Transplant
Lauring, Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: A prospective observational study
Lee, Hsieh, Ko, Molnupiravir-A novel oral anti-SARS-CoV-2 agent, Antibiotics
Nealon, Cowling, Omicron severity: Milder but not mild, Lancet
Nyberg, Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron, Lancet
Pontolillo, Molnupiravir as an early treatment for COVID-19: A real life study, Pathogens
Sheahan, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci. Transl. Med
Takashita, E cacy of antibodies and antiviral drugs against Covid-19 omicron variant, N. Engl. J. Med
Tenforde, Association between mRNA vaccination and COVID-19 hospitalization and disease severity, JAMA
Thompson, Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance -VISION network, 10 states, MMWR Morb. Mortal. Wkly Rep
Ulloa, Buchan, Daneman, Brown, Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada, JAMA
Wahl, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature
Wen, E cacy and safety of three new oral antiviral treatment (molnupiravir, uvoxamine and Paxlovid) for COVID-19: a meta-analysis, Ann. Med
Wong, Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: A retrospective cohort study, Lancet Infect. Dis
Yoon, Orally e cacious broad-spectrum ribonucleoside analog inhibitor of in uenza and respiratory syncytial viruses, Antimicrob. Agents Chemother
Zhao, The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis, J. Med. Virol
{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2023, 4, 5]], 'date-time': '2023-04-05T04:43:20Z', 'timestamp': 1680669800369}, 'posted': {'date-parts': [[2023, 1, 16]]}, 'group-title': 'In Review', 'reference-count': 31, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T00:00:00Z', 'timestamp': 1673827200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2023, 1, 7]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Molnupiravir is among the antiviral agents used to treat COVID-19; however, ' 'reported data on the efficacy of this drug are based on results from unvaccinated patients. ' 'As such, the efficacy of molnupiravir among vaccinated patients during the B1.1.529 (Omicron) ' 'variant outbreak remains unknown. To address this issue, this study retrospectively analyzed ' 'data from 294 vaccinated patients with COVID-19 who had at least one risk factor, between May ' 'and October 2022. Patients were divided into the molnupiravir group and the control group to ' 'investigate the correlations of molnupiravir and other factors with rates of hospitalization ' 'and death (hospitalization/death) within 28 days of admission. Potential risk factors were ' 'also examined. The study findings indicated that molnupiravir was not associated with the ' 'rate of hospitalization/death, while age\u2009≥\u200980 years, residence in a long-term care ' 'facility, and presence of chronic obstructive pulmonary disease were significantly associated ' 'with the rate of hospitalization/death. Although the current results suggest that the effect ' 'of vaccination in preventing severe illness against the Omicron variant is well maintained, ' 'additional studies on risk factors and outcomes are required to validate this study’s ' 'findings.</jats:p>', 'DOI': '10.21203/rs.3.rs-2451986/v1', 'type': 'posted-content', 'created': {'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T14:36:12Z', 'timestamp': 1673879772000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 ' 'during the Omicron surge in Japan', 'prefix': '10.21203', 'author': [ { 'given': 'Satoshi', 'family': 'Inaba', 'sequence': 'first', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Naoya', 'family': 'Nishioka', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Hisatoshi', 'family': 'Okumura', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Koshi', 'family': 'Nakao', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Yu', 'family': 'Hattori', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Shun', 'family': 'Futamura', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Tomohito', 'family': 'Hattori', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Kengo', 'family': 'Okabe', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}, { 'given': 'Daichi', 'family': 'Nishiyama', 'sequence': 'additional', 'affiliation': [{'name': 'Fukuchiyama City Hospital'}]}], 'member': '8761', 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'crossref', 'first-page': '1303', 'DOI': '10.1016/S0140-6736(22)00462-7', 'article-title': 'Comparative analysis of the risks of hospitalisation and death ' 'associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) ' 'variants in England: A cohort study', 'volume': '399', 'author': 'Nyberg T', 'year': '2022', 'unstructured': 'Nyberg, T. et al. Comparative analysis of the risks of hospitalisation ' 'and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta ' '(B.1.617.2) variants in England: A cohort study. Lancet 399, 1303–1312 ' '(2022).', 'journal-title': 'Lancet'}, { 'key': 'ref2', 'doi-asserted-by': 'crossref', 'first-page': '139', 'DOI': '10.15585/mmwr.mm7104e3', 'article-title': 'Effectiveness of a third dose of mRNA vaccines against ' 'COVID-19-associated emergency department and urgent care encounters and ' 'hospitalizations among adults during periods of Delta and omicron ' 'variant predominance - VISION network, 10 states, August 2021–January ' '2022', 'volume': '71', 'author': 'Thompson MG', 'year': '2022', 'unstructured': 'Thompson, M. G. et al. Effectiveness of a third dose of mRNA vaccines ' 'against COVID-19-associated emergency department and urgent care ' 'encounters and hospitalizations among adults during periods of Delta and ' 'omicron variant predominance - VISION network, 10 states, August ' '2021–January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 139–145 (2022).', 'journal-title': 'MMWR Morb. Mortal. Wkly Rep.'}, { 'key': 'ref3', 'first-page': '62', 'article-title': 'Orally efficacious broad-spectrum ribonucleoside analog inhibitor of ' 'influenza and respiratory syncytial viruses', 'author': 'Yoon JJ', 'year': '2018', 'unstructured': 'Yoon, J. J. et al. Orally efficacious broad-spectrum ribonucleoside ' 'analog inhibitor of influenza and respiratory syncytial viruses. ' 'Antimicrob. Agents Chemother. 62 (2018).', 'journal-title': 'Antimicrob. Agents Chemother.'}, { 'key': 'ref4', 'doi-asserted-by': 'crossref', 'first-page': '11', 'DOI': '10.1038/s41564-020-00835-2', 'article-title': 'Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 ' 'blocks SARS-CoV-2 transmission in ferrets', 'volume': '6', 'author': 'Cox RM', 'year': '2021', 'unstructured': 'Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically administered ' 'ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission ' 'in ferrets. Nat. Microbiol. 6, 11–18 (2021).', 'journal-title': 'Nat. Microbiol.'}, { 'key': 'ref5', 'doi-asserted-by': 'crossref', 'DOI': '10.1126/scitranslmed.abb5883', 'article-title': 'An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in ' 'human airway epithelial cell cultures and multiple coronaviruses in ' 'mice', 'volume': '12', 'author': 'Sheahan TP', 'year': '2020', 'unstructured': 'Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral ' 'inhibits SARS-CoV-2 in human airway epithelial cell cultures and ' 'multiple coronaviruses in mice. Sci. Transl. Med. 12 (2020).', 'journal-title': 'Sci. Transl. Med.'}, { 'key': 'ref6', 'doi-asserted-by': 'crossref', 'first-page': '451', 'DOI': '10.1038/s41586-021-03312-w', 'article-title': 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801', 'volume': '591', 'author': 'Wahl A', 'year': '2021', 'unstructured': 'Wahl, A. et al. SARS-CoV-2 infection is effectively treated and ' 'prevented by EIDD-2801. Nature 591, 451–457 (2021).', 'journal-title': 'Nature'}, { 'key': 'ref7', 'doi-asserted-by': 'crossref', 'first-page': '749', 'DOI': '10.1093/infdis/jiab361', 'article-title': 'Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants ' 'of concern in a hamster infection model', 'volume': '224', 'author': 'Abdelnabi R', 'year': '2021', 'unstructured': 'Abdelnabi, R. et al. Molnupiravir inhibits replication of the emerging ' 'SARS-CoV-2 variants of concern in a hamster infection model. J. Infect. ' 'Dis. 224, 749–753 (2021).', 'journal-title': 'J. Infect. Dis.'}, { 'key': 'ref8', 'first-page': '93', 'article-title': 'Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a ' 'proofreading-intact coronavirus with a high genetic barrier to ' 'resistance', 'author': 'Agostini ML', 'year': '2019', 'unstructured': 'Agostini, M. L. et al. Small-molecule antiviral β-d-N4-hydroxycytidine ' 'inhibits a proofreading-intact coronavirus with a high genetic barrier ' 'to resistance. J. Virol. 93 (2019).', 'journal-title': 'J. Virol.'}, { 'key': 'ref9', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal A', 'year': '2022', 'unstructured': 'Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in ' 'nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref10', 'doi-asserted-by': 'crossref', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'article-title': 'Remdesivir for the treatment of Covid-19 - Final report', 'volume': '383', 'author': 'Beigel JH', 'year': '2020', 'unstructured': 'Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - Final ' 'report. N. Engl. J. Med. 383, 1813–1826 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref11', 'doi-asserted-by': 'crossref', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'article-title': 'Efficacy of antibodies and antiviral drugs against Covid-19 omicron ' 'variant', 'volume': '386', 'author': 'Takashita E', 'year': '2022', 'unstructured': 'Takashita, E. et al. Efficacy of antibodies and antiviral drugs against ' 'Covid-19 omicron variant. N. Engl. J. Med. 386, 995–998 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref12', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19', 'volume': '386', 'author': 'Hammond J', 'year': '2022', 'unstructured': 'Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized ' 'adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref13', 'doi-asserted-by': 'crossref', 'first-page': '452', 'DOI': '10.1038/bmt.2012.244', 'article-title': 'Investigation of the freely available easy-to-use software ‘EZR’ for ' 'medical statistics', 'volume': '48', 'author': 'Kanda Y', 'year': '2013', 'unstructured': 'Kanda, Y. Investigation of the freely available easy-to-use software ' '‘EZR’ for medical statistics. Bone Marrow Transplant. 48, 452–458 ' '(2013).', 'journal-title': 'Bone Marrow Transplant.'}, { 'key': 'ref14', 'first-page': '10', 'article-title': 'Molnupiravir-A novel oral anti-SARS-CoV-2 agent', 'author': 'Lee CC', 'year': '2021', 'unstructured': 'Lee, C. C., Hsieh, C. C. & Ko, W. C. Molnupiravir-A novel oral ' 'anti-SARS-CoV-2 agent. Antibiotics (Basel) 10 (2021).', 'journal-title': 'Antibiotics (Basel)'}, { 'key': 'ref15', 'doi-asserted-by': 'crossref', 'first-page': '516', 'DOI': '10.1080/07853890.2022.2034936', 'article-title': 'Efficacy and safety of three new oral antiviral treatment ' '(molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis', 'volume': '54', 'author': 'Wen W', 'year': '2022', 'unstructured': 'Wen, W. et al. Efficacy and safety of three new oral antiviral treatment ' '(molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. ' 'Ann. Med. 54, 516–523 (2022).', 'journal-title': 'Ann. Med.'}, { 'key': 'ref16', 'doi-asserted-by': 'crossref', 'first-page': '508', 'DOI': '10.1016/j.jsps.2022.03.002', 'article-title': 'The pill of recovery; Molnupiravir for treatment of COVID-19 patients; ' 'a systematic review', 'volume': '30', 'author': 'Kamal L', 'year': '2022', 'unstructured': 'Kamal, L., Ramadan, A., Farraj, S., Bahig, L. & Ezzat, S. The pill of ' 'recovery; Molnupiravir for treatment of COVID-19 patients; a systematic ' 'review. Saudi Pharm. J. 30, 508–518 (2022).', 'journal-title': 'Saudi Pharm. J.'}, { 'key': 'ref17', 'doi-asserted-by': 'crossref', 'first-page': '5582', 'DOI': '10.1002/jmv.28011', 'article-title': 'Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A ' 'real-life experience', 'volume': '94', 'author': 'Vito A', 'year': '2022', 'unstructured': 'De Vito, A. et al. Safety and efficacy of molnupiravir in ' 'SARS-CoV-2-infected patients: A real-life experience. J. Med. Virol. 94, ' '5582–5588 (2022).', 'journal-title': 'J. Med. Virol.'}, { 'key': 'ref18', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/pathogens11101121', 'article-title': 'Molnupiravir as an early treatment for COVID-19: A real life study', 'volume': '11', 'author': 'Pontolillo M', 'year': '2022', 'unstructured': 'Pontolillo, M. et al. Molnupiravir as an early treatment for COVID-19: A ' 'real life study. Pathogens 11 (2022).', 'journal-title': 'Pathogens'}, { 'key': 'ref19', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1038/s41392-022-00997-x', 'article-title': 'SARS-CoV-2 Omicron variant: Recent progress and future perspectives', 'volume': '7', 'author': 'Fan Y', 'year': '2022', 'unstructured': 'Fan, Y. et al. SARS-CoV-2 Omicron variant: Recent progress and future ' 'perspectives. Signal Transduct. Target. Ther. 7, 141 (2022).', 'journal-title': 'Signal Transduct. Target. Ther.'}, { 'key': 'ref20', 'doi-asserted-by': 'crossref', 'first-page': 'n3103', 'DOI': '10.1136/bmj.n3103', 'article-title': 'Covid-19: Runny nose, headache, and fatigue are commonest symptoms of ' 'omicron, early data show', 'volume': '375', 'author': 'Iacobucci G', 'year': '2021', 'unstructured': 'Iacobucci, G. Covid-19: Runny nose, headache, and fatigue are commonest ' 'symptoms of omicron, early data show. BMJ 375, n3103 (2021).', 'journal-title': 'BMJ'}, { 'key': 'ref21', 'first-page': '838', 'article-title': 'SARS-CoV-2 Omicron variant: Characteristics and prevention', 'volume': '2', 'author': 'He X', 'year': '2021', 'unstructured': 'He, X., Hong, W., Pan, X., Lu, G. & Wei, X. SARS-CoV-2 Omicron variant: ' 'Characteristics and prevention. Med. 2, 838–845 (2021).', 'journal-title': 'Med.'}, { 'key': 'ref22', 'doi-asserted-by': 'crossref', 'first-page': '412', 'DOI': '10.1016/S0140-6736(22)00056-3', 'article-title': 'Omicron severity: Milder but not mild', 'volume': '399', 'author': 'Nealon J', 'year': '2022', 'unstructured': 'Nealon, J. & Cowling, B. J. Omicron severity: Milder but not mild. ' 'Lancet 399, 412–413 (2022).', 'journal-title': 'Lancet'}, { 'key': 'ref23', 'doi-asserted-by': 'crossref', 'first-page': '1286', 'DOI': '10.1001/jama.2022.2274', 'article-title': 'Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada', 'volume': '327', 'author': 'Ulloa AC', 'year': '2022', 'unstructured': 'Ulloa, A. C., Buchan, S. A., Daneman, N. & Brown, K. A. Estimates of ' 'SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA 327, ' '1286–1288 (2022).', 'journal-title': 'JAMA'}, { 'key': 'ref24', 'doi-asserted-by': 'crossref', 'first-page': '2043', 'DOI': '10.1001/jama.2021.19499', 'article-title': 'Association between mRNA vaccination and COVID-19 hospitalization and ' 'disease severity', 'volume': '326', 'author': 'Tenforde MW', 'year': '2021', 'unstructured': 'Tenforde, M. W. et al. Association between mRNA vaccination and COVID-19 ' 'hospitalization and disease severity. JAMA 326, 2043–2054 (2021).', 'journal-title': 'JAMA'}, { 'key': 'ref25', 'doi-asserted-by': 'crossref', 'first-page': '1532', 'DOI': '10.1056/NEJMoa2119451', 'article-title': 'Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant', 'volume': '386', 'author': 'Andrews N', 'year': '2022', 'unstructured': 'Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron ' '(B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref26', 'article-title': 'Clinical severity and mRNA vaccine effectiveness for omicron, delta, ' 'and alpha SARS-CoV-2 variants in the United States: A prospective ' 'observational study', 'author': 'Lauring AS', 'year': '2022', 'unstructured': 'Lauring, A. S. et al. Clinical severity and mRNA vaccine effectiveness ' 'for omicron, delta, and alpha SARS-CoV-2 variants in the United States: ' 'A prospective observational study. medRxiv (2022).', 'journal-title': 'medRxiv'}, { 'key': 'ref27', 'article-title': 'Molnupiravir plus usual care versus usual care alone as early treatment ' 'for adults with COVID-19 at increased risk of adverse outcomes ' '(PANORAMIC): An open-label, platform-adaptive randomised controlled ' 'trial', 'author': 'Butler CC', 'year': '2022', 'unstructured': 'Butler, C. C. et al. Molnupiravir plus usual care versus usual care ' 'alone as early treatment for adults with COVID-19 at increased risk of ' 'adverse outcomes (PANORAMIC): An open-label, platform-adaptive ' 'randomised controlled trial. Lancet (2022).', 'journal-title': 'Lancet'}, { 'key': 'ref28', 'doi-asserted-by': 'crossref', 'first-page': '1681', 'DOI': '10.1016/S1473-3099(22)00507-2', 'article-title': 'Real-world effectiveness of early molnupiravir or ' 'nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without ' 'supplemental oxygen requirement on admission during Hong Kong’s omicron ' 'BA.2 wave: A retrospective cohort study', 'volume': '22', 'author': 'Wong CKH', 'year': '2022', 'unstructured': 'Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or ' 'nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without ' 'supplemental oxygen requirement on admission during Hong Kong’s omicron ' 'BA.2 wave: A retrospective cohort study. Lancet Infect. Dis. 22, ' '1681–1693 (2022).', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': 'ref29', 'doi-asserted-by': 'crossref', 'first-page': '1915', 'DOI': '10.1002/jmv.25889', 'article-title': 'The impact of COPD and smoking history on the severity of COVID-19: A ' 'systemic review and meta-analysis', 'volume': '92', 'author': 'Zhao Q', 'year': '2020', 'unstructured': 'Zhao, Q. et al. The impact of COPD and smoking history on the severity ' 'of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 92, ' '1915–1921 (2020).', 'journal-title': 'J. Med. Virol.'}, { 'key': 'ref30', 'doi-asserted-by': 'crossref', 'first-page': '100789', 'DOI': '10.1016/j.eclinm.2021.100789', 'article-title': 'COPD and the risk of poor outcomes in COVID-19: A systematic review and ' 'meta-analysis', 'volume': '33', 'author': 'Gerayeli FV', 'year': '2021', 'unstructured': 'Gerayeli, F. V. et al. COPD and the risk of poor outcomes in COVID-19: A ' 'systematic review and meta-analysis. EClinicalmedicine 33, 100789 ' '(2021).', 'journal-title': 'EClinicalmedicine'}, { 'key': 'ref31', 'doi-asserted-by': 'crossref', 'first-page': '712', 'DOI': '10.1164/rccm.202108-1901OC', 'article-title': 'Increased SARS-CoV-2 infection, protease, and inflammatory responses in ' 'chronic obstructive pulmonary disease primary bronchial epithelial ' 'cells defined with single-cell RNA sequencing', 'volume': '206', 'author': 'Johansen MD', 'year': '2022', 'unstructured': 'Johansen, M. D. et al. Increased SARS-CoV-2 infection, protease, and ' 'inflammatory responses in chronic obstructive pulmonary disease primary ' 'bronchial epithelial cells defined with single-cell RNA sequencing. Am. ' 'J. Respir. Crit. Care Med. 206, 712–729 (2022).', 'journal-title': 'Am. J. Respir. Crit. Care Med.'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-2451986/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-2451986/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 4, 4]], 'date-time': '2023-04-04T12:16:10Z', 'timestamp': 1680610570000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-2451986/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 16]]}, 'references-count': 31, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-2451986/v1', 'relation': {}, 'published': {'date-parts': [[2023, 1, 16]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit